Table 2 Characterisation of MRSA strains detected within this study
CC | Strain | Number and percentage of isolates | Resistance-associated genes | Virulence-associated genes | Other relevant markers |
|---|---|---|---|---|---|
1 | CC1-IV/SCC fus (WA MRSA-1/45) | 1 (0.93%) | mecA (SCCmec IV), blaZ/I/R, ccrA/B-1, Q6GD50 (fusC) | lukD/E, sea, seh, sek, seq, sak/scn, | agr III, capsule type 8, cna, sasG |
| Â | CC1/ST772-V [PVL+] (Bengal Bay Clone) | 1 (0.93%) | mecA (SCCmec V), blaZ/I/R, msr(A), mph(C) aacA-aphD, aphA3/sat | lukF/S-PV, sea, sec, sel, egc- cluster, ORF CM14, scn | agr II, capsule type 5, cna, sasG |
5 | CC5-IV (Paediatric Clone) | 3 (2.80%) | mecA (SCCmec IV), blaZ/I/R, erm(C) (in 2/3) | lukD/E, seb (in 1/3), egc- cluster, edinA (in 1/3) | agr II, capsule type 5, sasG |
| Â | CC5-IV [PVL+] (Paediatric Clone) | 2 (1.87%) | mecA (SCCmec IV), blaZ/I/R (in 1/2), erm(C), aphA3/sat (in 1/2) | lukF/S-PV, lukD/E, sea-N315, sed/j/r (in 1/2), egc- cluster, sak/scn, | agr II, capsule type 5, sasG |
| Â | CC5-IV/SCC fus ("Maltese Clone", see [22]) | 3 (2.80%) | mecA (SCCmec IV), ccrA-3, Q6GD50 (fusC), blaZ/I/R (in 2/3) | lukD/E, tst1 (in 1/3), sea, sec/l (in 1/3), egc- cluster, sak/scn | agr II, capsule type 5, sasG |
| Â | CC5-V | 1 (0.93%) | mecA (SCCmec V), aacA-aphD | lukD/E, sea-N315, sed/j/r, egc- cluster, sak/scn | agr II, capsule type 5, sasG |
6 | CC6-IV (WA MRSA-51/66) | 3 (2.80%) | mecA (SCCmec IV), blaZ/I/R | lukD/E, sea, sak/scn | agr I, capsule type 8, cna, sasG |
8 | CC8/ST239-III (Vienna/Hungarian/Brazilian Clone) | 22 (20.56%) | mecA (SCCmec III), merA/B (in14/22), ccrC (in 21/22), blaZ/I/R, erm(A) (in 21/22), erm(C) (in 1/22), aacA-aphD (in 13/22), aphA3/sat (in 13/22), tet(M). tet(K) (in 3/22), cat (in 1/22), qacA (in 20/22) | lukD/E, sea (in 1/22), sek/q, sak/scn, chp (in 1/22) | agr I, capsule type 8, cna, sasG |
9 | CC9/ST834-(atyp. SCC mec ) | 1 (0.93%) | mecA, delta mecR, ugpQ, Q9XB68-dcs, ccrB- 4, Q6GD50 (fusC), blaZ/I/R, msr(A) | lukD/E, tst1, sec/l, sak/chp/scn | agr I, capsule type 8, sasG |
22 | CC22-IV (Barnim/UK-EMRSA-15) | 10, including 2 environmental samples (9.35%) | mecA (SCCmec IV), blaZ/I/R, erm(C) (in 1/10), msr(A) (in 1/10), aacA-aphD (in 1/10), tet(K) (in 1/10), dfrA | tst1 (in 6/10), egc- cluster, sak/chp/scn (in 9/10)/ | agr I, capsule type 5, cna, sasG |
| Â | CC22-IV [PVL+] | 20, including 2 environmental samples (18.69%) | mecA (SCCmec IV), blaZ/I/R, erm(C) (in 17/20), aacA-aphD, aadD (in 8/20), dfrA (in 19/20) | lukF/S-PV, egc- cluster, sak/chp/scn | agr I, capsule type 5, cna, sasG |
30 | CC30-IV [PVL+] (USA1100, Southwest Pacific or WSPP Clone) | 13, including 1 environmental sample (12.15%) | mecA (SCCmec IV), blaZ/I/R (in 12/13), erm(C) (in 1/13), msr(A)/mph(C) (in 6/13), aphA3/sat (in 6/13) | lukF/S-PV, egc- cluster, sak/chp/scn | agr III, capsule type 8, cna |
45 | CC45/ agr IV-IV (WA MRSA-23) | 1 (0.93%) | mecA (SCCmec IV), blaZ/I/R | sej/r, egc- cluster, sak/chp/scn | agr IV, capsule type 8, cna, sasG |
80 | CC80-IV | 2 (1.87%) | mecA (SCCmec IV), blaZ/I/R, erm(C), aphA3/sat (in 1/2), far1 (in 1/2) | lukD/E, seb/k/q (in 1/2), edinB, etD, sak/scn, chp (in 1/2) | agr III, capsule type 8, sasG |
| Â | CC80-IV [PVL+] (European caMRSA Clone) | 19 (17.76%) | mecA (SCCmec IV), blaZ/I/R (in 16/19), erm(C) (in 4/19), aphA3/sat (in 16/19), far1 (in 17/19), tet(K) (in 2/19) | lukF/S-PV, lukD/E, edinB, etD, sak/chp/scn | agr III, capsule type 8, sasG |
88 | CC88-IV [PVL+] | 3 (2.80%) | mecA (SCCmec IV), blaZ/I/R, tet(K) (in 2/3) | lukF/S-PV, lukD/E, sea-N315 (in 2/3), sak/chp/scn (in 2/3) | agr III, capsule type 8, sasG |
97 | CC97-V | 2 (1.87%) | mecA (SCCmec V), Q6GD50 (fusC), blaZ/I/R, aacA-aphD (in 1/2), tet(K) (in 1/2) | lukD/E, sak/scn | agr I, capsule type 5, sasG |